Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Denny

Showing results (21-30 of 748) with videos related to

Pageof 75
Sort By:
Pharmacology & Therapeutics|August 23, 2002
Irreversible inhibitors of the erbB family of protein tyrosine kinasesWilliam A Denny
Current Pharmaceutical Design|June 8, 2002
Nitroreductase-based GDEPTWilliam A Denny
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Prospects for hypoxia-activated anticancer drugsWilliam A Denny
Expert Opinion on Investigational Drugs|July 2, 2005
The 134th British Pharmaceutical ConferenceW A Denny
Expert Opinion on Investigational Drugs|July 2, 2005
Dual topoisomerase I/II poisons as anticancer drugsW A Denny
Future Oncology (London, England)|March 13, 2010
Hypoxia-activated prodrugs in cancer therapy: progress to the clinicWilliam A Denny
Journal of Medicinal Chemistry|March 14, 2012
Giving anemia a boost with inhibitors of prolyl hydroxylaseWilliam A Denny
Anti-Cancer Drug Design|December 1, 1989
DNA-intercalating ligands as anti-cancer drugs: prospects for future designW A Denny
Pediatric Emergency Care|January 3, 2018
Septic Arthritis, Osteomyelitis, and Pyomyositis in a Previously Healthy InfantKatherine Bline, Sarah A Denny
The Journal of Organic Chemistry|December 7, 2002
A new short synthesis of 3-substituted 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles (amino-CBIs)Shangjin Yang, William A Denny
Pageof 75

Showing results (21-30 of 748) with videos related to

Sort By:
Pageof 75
Pharmacology & Therapeutics|August 23, 2002
Irreversible inhibitors of the erbB family of protein tyrosine kinasesWilliam A Denny
Current Pharmaceutical Design|June 8, 2002
Nitroreductase-based GDEPTWilliam A Denny
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Prospects for hypoxia-activated anticancer drugsWilliam A Denny
Expert Opinion on Investigational Drugs|July 2, 2005
The 134th British Pharmaceutical ConferenceW A Denny
Expert Opinion on Investigational Drugs|July 2, 2005
Dual topoisomerase I/II poisons as anticancer drugsW A Denny
Future Oncology (London, England)|March 13, 2010
Hypoxia-activated prodrugs in cancer therapy: progress to the clinicWilliam A Denny
Journal of Medicinal Chemistry|March 14, 2012
Giving anemia a boost with inhibitors of prolyl hydroxylaseWilliam A Denny
Anti-Cancer Drug Design|December 1, 1989
DNA-intercalating ligands as anti-cancer drugs: prospects for future designW A Denny
Pediatric Emergency Care|January 3, 2018
Septic Arthritis, Osteomyelitis, and Pyomyositis in a Previously Healthy InfantKatherine Bline, Sarah A Denny
The Journal of Organic Chemistry|December 7, 2002
A new short synthesis of 3-substituted 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benzo[e]indoles (amino-CBIs)Shangjin Yang, William A Denny
Pageof 75